Abstract
The Viepoint discusses several points regarding whether there is enough data to accept neoadjuvant immunotherapy as a daily practice for patients with operable non–small cell lung cancer.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
